Jim Cramer's Prudent Take: Natera Soars, But Should Investors Hit the Brakes?

When a stock is absolutely on fire, it's easy for investors to get swept up in the excitement, isn't it? Well, CNBC's 'Mad Money' host, Jim Cramer, known for his often fervent takes, offered a dose of tempered wisdom regarding Natera (NTRA) on September 3, 2026. His message was clear: while Natera's recent performance is certainly eye-popping, perhaps it's best to pump the brakes a little. As he put it, he'd "put Natera on [his] watch list and not chase the stock here." A classic Cramer moment, urging caution amidst the fervor.

And let's be honest, there's been plenty of fervor around Natera. The company, a leader in molecular diagnostics, just wrapped up a truly stellar second quarter for 2026. We're talking about revenue hitting a whopping $752.8 million, which wasn't just a 37.7% jump year-over-year, but it also comfortably sailed past analyst expectations of $661 million. That's a significant beat, by any measure. They processed a record-breaking 1.04 million tests, with their crucial Clinical MRD/Signatera volume surging an impressive 56%. Even the net loss narrowed more than anticipated, coming in at $0.47 per share against an expected $0.51 loss. Clearly, things are trending in the right direction.

Following such robust numbers, Natera's shares, not surprisingly, initially exploded, surging over 21% to touch a fresh 52-week high after the Q2 report. Even after some regular trading fluctuations that saw a slight dip, the stock extended its gains significantly after hours, closing up 1.37% at $325.17. The company's CEO, Steve Chapman, wasn't shy about expressing his enthusiasm, stating quite directly that Natera is "clearly on a roll." And why wouldn't he be? They even raised their full-year 2026 revenue guidance to an impressive $2.85 billion-$2.91 billion, blowing past previous estimates and analyst forecasts.

A lot of this momentum, it seems, can be attributed to the success of their key offerings. The Signatera MRD test, for instance, showcased phenomenal new clinical validation data in Blood Neoplasia, boasting a 100% positive predictive value for treatment response and detecting lymphoma recurrence earlier than traditional imaging. Plus, expanded MolDx reimbursement coverage for their Prospera Transplant testing has certainly added fuel to the bullish fire. These aren't just incremental improvements; they're significant advancements pushing the company forward.

However, despite all this good news and the CEO's beaming optimism, Cramer's advice comes with a solid foundation. While many analysts are indeed bullish on Natera, pointing to improving margins and strong fundamentals, some have begun to sound a note of caution. The stock has enjoyed an approximate 80% rally, and a few voices on Wall Street are suggesting it might be getting a little, shall we say, 'overextended.' It’s a classic Wall Street dilemma: how much good news is already baked into the price?

Consider this: the median analyst price target for Natera was around $275. If the stock is trading well above that, it signals a potential valuation stretch. Some even flagged the stock as possibly overvalued relative to fundamental value estimates, which hovered closer to $205. Add to that the intensifying competition in the liquid biopsy diagnostics space, with strong players like Guardant Health vying for market share, and you start to see why prudence might be warranted. And yes, there were some insider stock sales, though it's important to remember these are often tied to planned RSU vesting and 10b5-1 plans, not necessarily a sign of a lack of confidence.

So, what's an investor to do? Cramer's counsel seems to be a pragmatic one. Natera is undoubtedly a company with incredible innovation and impressive growth. The fundamentals look strong, and their products are making a real difference. But in the volatile world of the stock market, even the best stories can become overbought. Perhaps it's a moment to admire the company's achievements from a comfortable distance, adding it to your watchlist, and patiently waiting for a potentially more opportune entry point. Sometimes, the smartest move isn't to chase the rocket but to prepare for its next launch from solid ground.